Diflucan penetration into the CSF is excellent, a key pharmacological advantage.

Diflucan’s efficacy can be reduced by concomitant use of rifampin.

Not effective against Scedosporium or Fusarium species, important emerging pathogens.

Diflucan is a standard part of the workup for a patient with suspected invasive fungal infection.

Diflucan can cause headaches and gastrointestinal upset as common side effects.

Concomitant Diflucan and warfarin requires intense INR monitoring due to increased bleeding risk.

Diflucan is not active against the dimorphic fungus Blastomyces dermatitidis.

Diflucan is a critical part of the antifungal arsenal in resource-limited settings.

The “trailing effect” in Diflucan susceptibility testing can complicate interpretation.

Not recommended for empirical treatment of serious infections in critically ill patients.